TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

ABSTRACT: This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving TAS-102, irinotecan, and bevacizumab may work better in treating patients with colorectal cancer compared to traditional chemotherapy and bevacizumab.

DISEASE(S): Adenocarcinoma,Stage Iva Colorectal Cancer Ajcc V8,Stage Ivb Rectal Cancer Ajcc V8,Carcinoma,Stage Iii Colon Cancer Ajcc V8,Stage Iiic Colorectal Cancer Ajcc V8,Metastatic Colon Adenocarcinoma,Stage Ivc Rectal Cancer Ajcc V8,Stage Ivb Colorectal Cancer Ajcc V8,Stage Iv Colon Cancer Ajcc V8,Stage Iiib Rectal Cancer Ajcc V8,Stage Iiia Colon Cancer Ajcc V8,Unresectable Colon Adenocarcinoma,Colorectal Neoplasms,Stage Ivc Colon Cancer Ajcc V8,Recurrent Rectal Adenocarcinoma,Stage Iiic Colon Cancer Ajcc V8,Recurrent Colon Adenocarcinoma,Stage Iiib Colorectal Cancer Ajcc V8,Stage Ivc Colorectal Cancer Ajcc V8,Unresectable Colorectal Carcinoma,Advanced Colorectal Carcinoma,Metastatic Rectal Adenocarcinoma,Stage Iiia Colorectal Cancer Ajcc V8,Stage Ivb Colon Cancer Ajcc V8,Unresectable Rectal Adenocarcinoma,Stage Iva Rectal Cancer Ajcc V8,Rectal Neoplasms,Stage Iii Rectal Cancer Ajcc V8,Stage Iii Colorectal Cancer Ajcc V8,Recurrent Colorectal Adenocarcinoma,Colonic Neoplasms

PROVIDER: 2317842 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR